Danaher (NYSE:DHR) issued an update on its second quarter earnings guidance on Thursday morning. The company provided earnings per share guidance of $1.13-1.16 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.20. Danaher also updated its FY 2019 guidance to $4.72-4.80 EPS.
DHR traded up $0.34 during trading on Friday, reaching $131.68. 1,587,625 shares of the company’s stock were exchanged, compared to its average volume of 2,622,772. The firm has a market capitalization of $94.03 billion, a price-to-earnings ratio of 29.13, a PEG ratio of 2.54 and a beta of 1.02. Danaher has a one year low of $94.59 and a one year high of $134.67. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.18 and a quick ratio of 1.74.
Danaher (NYSE:DHR) last issued its quarterly earnings results on Thursday, April 18th. The conglomerate reported $1.07 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.01 by $0.06. Danaher had a net margin of 12.04% and a return on equity of 11.61%. The firm had revenue of $4.88 billion for the quarter, compared to the consensus estimate of $4.80 billion. During the same quarter in the previous year, the company earned $0.99 EPS. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. As a group, equities research analysts predict that Danaher will post 4.77 EPS for the current year.
Several research analysts have weighed in on DHR shares. Zacks Investment Research downgraded shares of Danaher from a buy rating to a hold rating in a report on Tuesday, April 23rd. Deutsche Bank upped their target price on shares of Danaher to $130.00 and gave the stock a buy rating in a research note on Tuesday, February 26th. Jefferies Financial Group increased their price target on shares of Danaher to $140.00 and gave the company a buy rating in a research report on Tuesday, February 26th. UBS Group increased their price target on shares of Danaher from $125.00 to $144.00 and gave the company a buy rating in a research report on Tuesday, February 26th. Finally, Needham & Company LLC restated a buy rating and set a $141.00 price target (up previously from $138.00) on shares of Danaher in a research report on Wednesday, April 17th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $131.75.
In related news, SVP Angela S. Lalor sold 4,534 shares of Danaher stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $127.25, for a total value of $576,951.50. Following the sale, the senior vice president now owns 21,209 shares in the company, valued at $2,698,845.25. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Rainer Blair sold 37,859 shares of Danaher stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $127.45, for a total transaction of $4,825,129.55. Following the completion of the sale, the insider now owns 32,661 shares in the company, valued at approximately $4,162,644.45. The disclosure for this sale can be found here. Insiders sold 424,761 shares of company stock worth $54,983,097 over the last ninety days. 11.40% of the stock is currently owned by insiders.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.